HRMY NASDAQ
Harmony Biosciences Holdings, Inc.
1W: -1.9%
1M: -10.7%
3M: +3.0%
YTD: -1.5%
1Y: +24.4%
3Y: +72.8%
5Y: -3.2%
$37.95
+1.12 (+3.04%)
After Hours: $37.04 (-0.91, -2.40%)
Weekly Expected Move ±5.1%
$32
$34
$36
$38
$40
Credit Risk of going bust: lower than 74% of companies Debt: 6.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.14B.
Distance to default 8.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.14B.
Distance to default 8.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range25.9-43.49
Volume850,295
Avg Volume924,301
Beta1.01
Dividend—
Analyst Ratings
Company Info
CEOJeffrey Dayno
Employees293
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-19
Websiteharmonybiosciences.com
630 West Germantown Pike
Plymouth Meeting, PA 19462
US
Plymouth Meeting, PA 19462
US
484 539 9800
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Latest News
Healthcare stocks with strong revenue growth and attractive valuations
BHC Q3 Earnings Preview: Here's What You Should Know
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
4 Small-Cap Stocks With Paths to Recovery After the Fed's September Rate Hike
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Budur Kumar | M-Exempt | 10,406 | $30.69 | 2026-09-18 |
| Budur Kumar | M-Exempt | 25,446 | $30.27 | 2026-09-18 |
| Budur Kumar | S-Sale | 35,852 | $43.05 | 2026-09-18 |
| Budur Kumar | M-Exempt | 10,406 | $30.69 | 2026-09-18 |
| Budur Kumar | M-Exempt | 25,446 | $30.27 | 2026-09-18 |